top of page

DNA Methylation Analysis

Overview

DNA methylation is a key epigenetic mechanism that plays a critical role in gene regulation. Leveraging this cutting-edge science, our DNA Methylation Analysis Technology enables early, accurate, and non-invasive cancer detection. This innovative approach provides unparalleled diagnostic precision, transforming how cancers are identified and managed.

皮特里盤帶吸管

A Strategic Partnership

Our advancements in DNA Methylation Analysis Technology are made possible through a close partnership with EG Biomed, a pioneering leader in cancer diagnostics. This collaboration combines EG Biomed's cutting-edge research and patented methodologies with YD Biopharma’s expertise in clinical applications and market distribution.

Exceptional Accuracy

Sensitivity:
Up to 99% for early-stage cancer detection.

Specificity:
Reduces false positives, ensuring reliable diagnosis.

Cost-Effective and Scalable

Low-cost testing platform based on qPCR ensures affordability without compromising accuracy.

Scalable infrastructure allows for rapid adoption across clinical and research settings.

Streamlined Workflow

User-friendly sample collection and analysis processes minimize complexity for both clinicians and laboratories.

Results are accessible via the EG Biocloud Report System, enabling seamless integration into clinical workflows.

Room Temperature Stability

Samples can be stored and transported at room temperature for up to 14 days, simplifying logistics and reducing costs.

Early Cancer/Progression Monitoring Detection

Identifies cancer-specific DNA methylation patterns, significantly improving patient prognosis.

Applicable to hard-to-detect/monitor cancers such as pancreatic cancer (hard-to-detect) and breast cancer (hard-to-monitor), where early intervention is critical.

Monitoring Treatment Response

Tracks changes in methylation profiles to evaluate the effectiveness of ongoing treatments.

Supports personalized therapy adjustments based on real-time patient data.

Post-Treatment Surveillance

Detects recurrence risks by monitoring methylation signals, ensuring comprehensive follow-up care.

Offers peace of mind to patients and clinicians by enabling proactive management.

Multi-Cancer Screening

Expands beyond single cancer types to screen for multiple malignancies simultaneously, enhancing diagnostic efficiency.

1000xBTK.png

EG Pancreatic Blood Test Kit

Through a simple blood draw, cell-free DNA can be collected and further analyzed for methylation patterns to identify cancer risks. Since early-stage pancreatic cancer is difficult to detect and its incidence is almost equal to its mortality rate, EG BioMed’s exclusive patented methylation test provides a precise and effective early risk assessment for pancreatic cancer.

1000x30T.png

EG Breast Blood Test Kit

Through a simple blood draw, helps breast cancer patients monitor treatment effectiveness and post-surgery follow-ups. Compared to traditional imaging tests, it has a higher potential to detect potential tumor cells earlier.

Product Line

Taiwan

High demand driven by increased diabetes prevalence and elevated pancreatic cancer risks.

United States

Targeting a potential market of 30 million tests annually with strategic lab partnerships and CAP certification.

Worldwide

Positioned to lead the USD 2.37 billion pancreatic cancer diagnostics market, projected to grow at a 6.53% CAGR by 2030.

Market Potential

YD Biopharma’s Role

Exclusive Commercialization Rights

YD Biopharma is the sole distributor of EG Biomed's DNA Methylation Analysis technology, ensuring global access to these groundbreaking solutions.

Integration into Clinical Practice

We leverage our extensive network and regulatory expertise to bring EG Biomed's innovations to hospitals, clinics, and laboratories worldwide.

Expanding Market Reach

We leverage our extensive network and regulatory expertise to bring EG Biomed's innovations to hospitals, clinics, and laboratories worldwide.

業務代表

Technological Edge

Our DNA Methylation Analysis technology, powered by cfDNA methylation and qPCR, surpasses traditional methods like CA19-9 and microRNA analysis. Unlike competitors relying on fragile RNA or high-cost NGS platforms, our approach ensures:

Greater stability and repeatability

Faster reporting times

Lower costs, making it accessible to a broader population

水樣

Experience the Future of Cancer Diagnostics

Join us in transforming cancer care through the power of DNA Methylation Analysis. With unparalleled accuracy, scalability, and versatility, we are unlocking new possibilities for early detection and better patient outcomes.

科學家與試管
bottom of page